MedPath

Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection

Phase 2
Terminated
Conditions
HIV Infections
Interventions
Registration Number
NCT00612898
Lead Sponsor
Avexa
Brief Summary

Apricitabine is a new NRTI which is active against drug-resistant HIV. NRTIs are often included as part of patients' treatment, but many HIV-infected patients develop resistance to commonly used NRTIs such as lamivudine (3TC) and emtricitabine (FTC). This study will examine whether including apricitabine as part of patients' treatment is more effective than including lamivudine,when patients change treatment because of drug resistance.

Detailed Description

ATC has potent antiviral activity both in vitro (against wild-type HIV-1 and HIV-1 with mutations in reverse transcriptase that confer resistance to NRTIs), and in clinical studies in both treatment-naïve and treatment-experienced patients with M184V, including in the presence of additional NRTI mutations in reverse transcriptase.

The M184V mutation is most commonly present amongst patients failing regimens containing either of the two deoxycytidine analogs lamivudine and emtricitabine. Whilst lamivudine therapy is often maintained in patients harboring the M184V mutation in some settings, there are no deoxycytidine analogs currently available that effectively suppress replication of HIV-1 containing the M184V/I mutation, particularly in the presence of other additional NRTI mutations.

The purpose of this study is to extend the efficacy and safety established in study AVX-201 of ATC in patients who are HIV-1 infected and have failed treatment with lamivudine or emtricitabine and have confirmed M184V/I mutation. Patients to be enrolled will be failing their current lamivudine- or emtricitabine-containing regimen and therefore have limited remaining NRTI treatment options. This study will investigate whether it is possible to improve control of HIV-1 viral replication by including ATC within a treatment experienced patient's new optimized background regimen following ART treatment failure.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
239
Inclusion Criteria
  • HIV-1 positive with M184V/I mutation in reverse transcriptase;
  • 18 years of age or older;
  • Currently taking lamivudine (3TC) or emtricitabine (FTC)
Exclusion Criteria
  • Female patients who are pregnant or breastfeeding;
  • Current hepatitis B virus (HBV) infection;
  • Current treatment for hepatitis C virus infection;
  • Renal function not adequate

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2lamivudine150mg BID lamivudine plus optimised background
1apricitabine800mg BID apricitabine plus optimised background
Primary Outcome Measures
NameTimeMethod
Proportion of patients with plasma HIV-1 RNA <50 copies/mL at W24week 24
Secondary Outcome Measures
NameTimeMethod
Proportion of patients with plasma HIV-1 RNA <50 copies/mL at W48week 48
Time to loss of virological response (TLOVR analysis; FDA algorithm) at W12, W24 and W48 (<50 copies/mL)week 12, 24, and 48

Trial Locations

Locations (100)

Summa Health System

🇺🇸

Akron, Ohio, United States

Nicholaos C Bellos, MD, PA

🇺🇸

Dallas, Texas, United States

University of Texas Medical Brach

🇺🇸

Galveston, Texas, United States

Sunnybrook Health Sciences Centre

🇨🇦

Toronto, Ontario, Canada

University Health Network

🇨🇦

Toronto, Ontario, Canada

Gary Richmond, MD

🇺🇸

Fort Lauderdale, Florida, United States

Azienda Ospedaliero-Universitaria di Modena Policlinico

🇮🇹

Modena, Italy

Azienda Ospedaliera Cotugno

🇮🇹

Napoli, Italy

Orlando Immunology Center

🇺🇸

Orlando, Florida, United States

Georgetown University

🇺🇸

Washington, District of Columbia, United States

George Washington University

🇺🇸

Washington, District of Columbia, United States

Saint Michael's Medical Center

🇺🇸

Newark, New Jersey, United States

I.D. Care, Inc.

🇺🇸

Hillsborough, New Jersey, United States

Rambam Medical Center

🇮🇱

Haifa, Israel

The Alfred

🇦🇺

Melbourne, Victoria, Australia

Royal Melbourne Hospital

🇦🇺

Parkville, Victoria, Australia

Ubc Downtown I.D. Clinic

🇨🇦

Vancouver, British Columbia, Canada

Carlton Clinic

🇦🇺

Carlton, Victoria, Australia

Prahran Market Clinic

🇦🇺

South Yarra, Victoria, Australia

The Chaim Sheba Medical Center

🇮🇱

Ramat-Gan, Israel

Via Libre

🇵🇪

Lima, Peru

Pharmongkutklao Hospital

🇹🇭

Bangkok, Thailand

Sirraj Hospital, Mahidol Universoty

🇹🇭

Bangkok, Thailand

Instituto De Investigacion Cientifica

🇵🇷

Ponce, Puerto Rico

The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)

🇹🇭

Bangkok, Thailand

Fenway Community Health Center

🇺🇸

Boston, Massachusetts, United States

Community Research Intiative of New England

🇺🇸

Boston, Massachusetts, United States

Therapeutic Concepts

🇺🇸

Houston, Texas, United States

Resarch Access Network

🇺🇸

Houston, Texas, United States

Swedish Medical Center

🇺🇸

Seattle, Washington, United States

Kaiser Permanente Medical Center

🇺🇸

San Francisco, California, United States

University of Hawaii

🇺🇸

Honolulu, Hawaii, United States

University of Kansas School of Medicine

🇺🇸

Wichita, Kansas, United States

Azienda Ospedaliera Universitaria di Ferrara Arcispedale S.Anna

🇮🇹

Ferrara, Italy

UAB, 845 19th St South, South Beville Biomedical Research Building

🇺🇸

Birmingham, Alabama, United States

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Southwest Center for HIV/AIDS

🇺🇸

Phoenix, Arizona, United States

Denver Health & Hospital Authority

🇺🇸

Denver, Colorado, United States

The Research & Education Institute

🇺🇸

Portland, Oregon, United States

Edgardo Rebagliati Hospital

🇵🇪

Lima, Peru

AIDS Research Alliance

🇺🇸

West Hollywood, California, United States

Living Hope Clinical Foundation, Inc

🇺🇸

Long Beach, California, United States

Infectious Disease Research Institute, Inc

🇺🇸

Tampa, Florida, United States

Treasure Coast Infectious Diseases Consultants

🇺🇸

Vero Beach, Florida, United States

Aids Research Consortium Of Atlanta Inc.

🇺🇸

Atlanta, Georgia, United States

Atlanta Infectious Disease Group, PC

🇺🇸

Atlanta, Georgia, United States

Northwestern University

🇺🇸

Chicago, Illinois, United States

North Texas Infectious Diseases Consultants, P.A.

🇺🇸

Dallas, Texas, United States

Central Texas Clinical Research

🇺🇸

Austin, Texas, United States

Tarrant County Infection Disease Associates

🇺🇸

Fort Worth, Texas, United States

DCOL Center for Clinical Research

🇺🇸

Longview, Texas, United States

407 Doctors

🇦🇺

Darlinghurst, New South Wales, Australia

Parramatta Sexual Health Clinic

🇦🇺

Parramatta, New South Wales, Australia

Westmead Hospital

🇦🇺

Westmead, New South Wales, Australia

Prins Leopold Institute voor Tropische Geneeskunde

🇧🇪

Antwerpen, Belgium

Melbourne Sexual Health Centre

🇦🇺

Carlton, Victoria, Australia

Hopitaux IRIS Sud

🇧🇪

Bruxelles, Belgium

Cliniques Universitaires Saint-Luc

🇧🇪

Bruxelles, Belgium

Centre Hospitalier Universitaire de Quebec

🇨🇦

Quebec, Canada

Hamilton Health Sciences Corporation

🇨🇦

Hamilton, Ontario, Canada

Charite-Universitatsmedizin Berlin

🇩🇪

Berlin, Germany

Universitatsklinikum Essen

🇩🇪

Essen, Germany

EPIMED GmbH

🇩🇪

Berlin, Germany

Ruhr-Universitat Bochum

🇩🇪

Bochum, Germany

Universitatsklinikum Bonn

🇩🇪

Bonn, Germany

Klinikum Dortmund gGmbH

🇩🇪

Dortmund, Germany

Klinikum der Johann-Wolfgang Goethe-Universitat

🇩🇪

Frankfurt, Germany

Praxis Dr.Schneider

🇩🇪

Furth, Germany

Dr. med. Birger Kuhlmann

🇩🇪

Hannover, Germany

Praxis fuer Innere Medizin

🇩🇪

Freiburg, Germany

Klinikum der Universitat Munchen - Innenstadt

🇩🇪

Munchen, Germany

Gemeinschaftspraxis E. Schnaitmann, Dr. med. A. Schaffert, Dr. med. A. Trein, Dr. med. E. Ibler

🇩🇪

Stuttgart, Germany

Praxis Dres. Ulmer, Frietsch, Muller

🇩🇪

Stuttgart, Germany

Soroka University Medical Center

🇮🇱

Beer-Sheva, Israel

Tel-Aviv Sourasky Medical Center

🇮🇱

Tel Aviv, Israel

Hadassah University Hospital Ein Kerem

🇮🇱

Jerusalem, Israel

Kaplan Medical Center

🇮🇱

Rehovot, Israel

Ospedale S.Maria Annunziata

🇮🇹

Antella, Italy

Fondazione Centro San Raffaele del Monte Tabor

🇮🇹

Milano, Italy

Ospedale Luigi Sacco

🇮🇹

Milano, Italy

Azienda Ospedaliera Universitaria San Martino

🇮🇹

Genova, Italy

Azienda Ospedaliera di Padova

🇮🇹

Padova, Italy

Hospital Nacional CASE-EsSalud

🇵🇪

Arequipa, Peru

Comprensorio Amedeo di Savoia - Birago Di Vische

🇮🇹

Torino, Italy

Istituto Nazionale Malattie Infettive "Lazzaro Spallanzani" IRCCS

🇮🇹

Roma, Italy

Investigaciones Medicas en Salud

🇵🇪

Lima, Peru

Hospital Dos de Mayo

🇵🇪

Lima, Peru

Hospital Nacional Cayetano Heredia

🇵🇪

Lima, Peru

University of Puerto Rico

🇵🇷

San Juan, Puerto Rico

Hope Clinical Research

🇵🇷

San Juan, Puerto Rico

Mahidol University Hospital for Tropical Diseases

🇹🇭

Bangkok, Thailand

Ramathibodi Hospital, Mahidol University

🇹🇭

Bangkok, Thailand

Maharaj Nakorn Chiang Mai, Chiang Mai University

🇹🇭

Chiang Mai, Thailand

Khon Kaen University

🇹🇭

Khon Kaen, Thailand

Bamrasnaradura Institution

🇹🇭

Nonthaburi, Thailand

Birmingham Heartlands Hospital

🇬🇧

Birmingham, United Kingdom

St Mary's Hospital

🇬🇧

London, United Kingdom

Royal Free Hospital

🇬🇧

London, United Kingdom

Guy's King's & St. Thomas' School of Medicine

🇬🇧

London, United Kingdom

St Bartholomew's Hospital

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath